Argaam

The UAE’s Ministry of Health and Prevention (MOHAP), has officially registered Beijing Institute of Biological Product’s inactivated COVID-19 vaccine as part of its efforts to combat the global pandemic.

The vaccine was registered upon request of Sinopharm CNBG.

MOHAP in collaboration with Department of Health Abu Dhabi (DOH) reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows that the inactivated vaccine has 86 percent efficacy against COVID-19 infection.

The vaccine also has 99 percent seroconversion rate of neutralizing antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease.

Furthermore, the analysis shows no serious safety concerns.

Last September, this vaccine was granted Emergency Use Authorization by MOHAP to protect frontline workers most at risk of COVID-19.

The UAE is conducting Post Authorization Safety Study (PASS) and Post Authorization Efficacy Study (PAES) of its EUA program.

The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone. The EUA vaccination program has effectively safeguarded the UAE frontline workers.

Powered by Argaam